Listed

Larimar Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2016

Filed with the SEC on Aug 5, 2016 and accepted by EDGAR at Aug 4, 2016, 18:07 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-04-01 to 2016-06-30$0us-gaap:Revenues
Revenue6 months2016-01-01 to 2016-06-30$0us-gaap:Revenues
Research and development3 months2016-04-01 to 2016-06-30$10.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2016-01-01 to 2016-06-30$22.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-04-01 to 2016-06-30−$15.1mus-gaap:OperatingIncomeLoss
Operating income6 months2016-01-01 to 2016-06-30−$32.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-04-01 to 2016-06-30$140.0kus-gaap:InterestExpense
Interest expense6 months2016-01-01 to 2016-06-30$300.0kus-gaap:InterestExpense
Net income3 months2016-04-01 to 2016-06-30−$15.0mus-gaap:NetIncomeLoss
Net income6 months2016-01-01 to 2016-06-30−$32.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-04-01 to 2016-06-30−$0.55us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2016-01-01 to 2016-06-30−$1.20us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2016-01-01 to 2016-06-30−$32.3mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure6 months2016-01-01 to 2016-06-30$660.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-06-30$20.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-06-30$153.2mus-gaap:AssetsCurrent
Total assetsAt period end2016-06-30$154.8mus-gaap:Assets
Current liabilitiesAt period end2016-06-30$10.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-06-30$12.6mus-gaap:Liabilities
Long-term debtAt period end2016-06-30$4.7mus-gaap:LongTermDebt
Shareholders' equityAt period end2016-06-30$142.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-16-672131. Last ingested by Listed: Nov 13, 2026, 17:49 ET. Listed shows no prices and gives no investment advice.